Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

IQVIA Holdings Inc. focuses on technology solutions and contract research services. The Company offers a broad range of solutions which includes clinical development strategies, therapeutic expertise, predictive and prescriptive analytics, and patient retention services. IQVIA Holdings serves consumer health, biopharma, and medical technology industries globally.
Website: iqvia.com



Growth: Pretty weak revenue growth rate 8.7%, there is acceleration compared to average historical growth rates 5.0%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -7.9%

Profitability: LTM EBITDA margin is positive, +22.1%. On average the margin is decreasing unsteadily. In the last quarter the company beat the estimated EPS, +1.7%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 97.8% higher than minimum and 1.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 25.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $29.9 mln (-0.064% of cap.)

Key Financials (Download financials)

Ticker: IQV
Share price, USD:  (+3.4%)271.04
year average price 228.12  


year start price 204.55 2025-10-17

min close price 163.70 2026-05-26

max close price 275.02 2026-09-24

current price 271.04 2026-10-16
Common stocks: 189 279 006

Dividend Yield:  0.0%
FCF Yield LTM: -0.8%
EV / LTM EBITDA: 17.4x
EV / EBITDA annualized: 20.5x
Last revenue growth (y/y):  +8.7%
Last growth of EBITDA (y/y):  +2.0%
Historical revenue growth:  +5.0%
Historical growth of EBITDA:  +6.8%
EV / Sales: 3.9x
Margin (EBITDA LTM / Revenue): 22.1%
Fundamental value created in LTM:
Market Cap ($m): 51 302
Net Debt ($m): 14 090
EV (Enterprise Value): 65 392
Price to Book: 8.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05seekingalpha.com

IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript

2026-02-05zacks.com

IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y

2026-02-05zacks.com

IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates

2026-02-04zacks.com

IQV or IDXX: Which Is the Better Value Stock Right Now?

2026-02-03zacks.com

Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics

2025-12-29zacks.com

Here's Why You Should Retain IQV Stock in Your Portfolio Now

2025-12-11seekingalpha.com

IQVIA: Increasingly Indispensable In Drug Development

2025-12-09zacks.com

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

2025-11-11seekingalpha.com

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-10-28zacks.com

IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-22 2024-10-31 2024-07-22 2024-05-02 2023-11-01 2023-08-01 2023-04-28 2022-10-27
acceptedDate 2025-10-28 16:31:55 2025-07-22 07:06:22 2025-02-13 07:39:45 2024-10-31 16:46:54 2024-07-22 16:26:49 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14 2022-02-16 16:22:34 2021-02-12 16:16:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 4 100M 4 017M 15 405M 3 896M 3 814M 3 740M 14 984M 3 736M 3 728M 3 652M 14 410M 3 562M 13 874M 11 359M
costOfRevenue 2 727M 2 694M 10 030M 2 518M 2 757M 2 708M 9 745M 2 426M 2 443M 2 398M 9 382M 2 321M 9 233M 7 500M
grossProfit 1 373M 1 323M 5 375M 1 378M 1 057M 1 032M 5 239M 1 310M 1 285M 1 254M 5 028M 1 241M 4 641M 3 859M
grossProfitRatio 0.335 0.329 0.354 0.277 0.276 0.351 0.345 0.343 0.348
researchAndDevelopmentExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 514M 509M 1 992M 522M 509M 508M 2 053M 502M 482M 513M 2 071M 517M 1 964M 1 789M
otherExpenses 306M 308M 1 181M 306M 67M -11M 1 209M 35M 16M 253M 1 158M 248M 1 284M 1 339M
operatingExpenses 820M 817M 3 173M 828M 509M 508M 3 262M 799M 741M 766M 3 229M 765M 3 248M 3 128M
costAndExpenses 3 547M 3 511M 13 203M 3 318M 3 266M 3 216M 13 007M 3 225M 3 184M 3 164M 12 611M 3 086M 12 481M 10 628M
interestIncome 13M 10M 47M 13M 12M 11M 36M 14M 4M 6M 13M 4M 6M 6M
interestExpense 189M 182M 670M 170M 163M 166M 672M 181M 169M 141M 416M 108M 375M 416M
depreciationAndAmortization 286M 276M 1 114M 278M 269M 264M 1 125M 297M 259M 302M 1 130M 248M 1 264M 1 287M
ebitda 883M 781M 3 453M 798M 817M 788M 3 256M 857M 823M 773M 2 909M 709M 2 767M 2 076M
ebitdaratio 0.215 0.194 0.205 0.214 0.211 0.229 0.221 0.212 0.199
operatingIncome 553M 506M 2 202M 550M 548M 524M 1 977M 481M 524M 471M 1 799M 472M 1 393M 731M
operatingIncomeRatio 0.135 0.126 0.141 0.144 0.14 0.129 0.141 0.129 0.133
totalOtherIncomeExpensesNet -145M -183M -533M -201M -84M -184M -518M 5M -4M -109M -448M -112M -259M -351M
incomeBeforeTax 408M 323M 1 669M 349M 436M 340M 1 459M 349M 375M 362M 1 351M 360M 1 134M 380M
incomeBeforeTaxRatio 0.1 0.08 0.09 0.114 0.091 0.093 0.101 0.099 0.101
incomeTaxExpense 76M 57M 296M 65M 75M 49M 101M 51M 81M 71M 260M 70M 163M 72M
netIncome 331M 266M 1 373M 285M 363M 288M 1 358M 303M 297M 289M 1 091M 283M 966M 279M
netIncomeRatio 0.081 0.066 0.073 0.095 0.077 0.081 0.08 0.079 0.079
eps 1.94 1.55 7.57 1.57 1.99 1.58 7.39 1.66 1.61 1.56 5.82 1.52 5.05 1.46
epsdiluted 1.93 1.54 1.55 1.97 1.56 1.63 1.59 1.53 1.49
weightedAverageShsOut 170M 172M 181M 182M 182M 182M 184M 183M 184M 186M 188M 187M 191M 191M
weightedAverageShsOutDil 172M 173M 183M 184M 184M 184M 186M 186M 187M 189M 191M 189M 195M 195M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-15 2022-02-16 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -623M -636M -403M -369M -410M
ebit 2 339M 2 131M 1 779M 1 503M 789M
nonOperatingIncomeExcludingInterest -137M -154M 20M -110M -58M
netIncomeFromContinuingOperations 1 373M 1 358M 1 091M 971M 308M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 1 373M 1 358M 1 091M 966M 279M
epsDiluted 7.49 7.29 5.72 4.95 1.43

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-22 2024-10-31 2024-07-22 2024-05-02 2023-11-01 2023-08-01 2023-04-28 2022-10-27
acceptedDate 2025-10-28 16:31:55 2025-07-22 07:06:22 2025-02-13 07:39:45 2024-10-31 16:46:54 2024-07-22 16:26:49 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14 2022-02-16 16:22:34 2021-02-12 16:16:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 814M 2 039M 1 702M 1 572M 1 545M 1 444M 1 376M 1 224M 1 382M 1 494M 1 216M 1 274M 1 366M 1 814M
shortTermInvestments 158M 149M 141M 140M 133M 131M 120M 108M 110M 104M 93M 87M 111M 88M
cashAndShortTermInvestments 1 972M 2 188M 1 843M 1 712M 1 678M 1 575M 1 496M 1 332M 1 492M 1 598M 1 309M 1 361M 1 477M 1 902M
netReceivables 3 314M 3 406M 3 240M 3 250M 3 296M 3 461M 3 413M 3 276M 3 184M 3 105M 2 960M 2 687M 2 609M 2 466M
inventory 0 0 0 0 0 0 0 177M 179M 165M 0 0 0 0
otherCurrentAssets 693M 751M 592M 670M 648M 615M 546M 423M 474M 460M 561M 704M 521M 563M
totalCurrentAssets 5 979M 6 345M 5 829M 5 632M 5 622M 5 651M 5 596M 5 208M 5 329M 5 328M 4 981M 4 752M 4 763M 5 090M
propertyPlantEquipmentNet 824M 816M 773M 772M 768M 791M 819M 790M 829M 845M 863M 840M 903M 953M
goodwill 15 948M 15 611M 14 710M 15 091M 14 477M 14 516M 14 567M 14 288M 14 178M 14 015M 13 921M 13 177M 13 301M 12 654M
intangibleAssets 4 707M 4 596M 4 499M 4 734M 4 608M 4 725M 4 839M 4 907M 4 942M 4 757M 4 820M 4 718M 4 943M 5 205M
goodwillAndIntangibleAssets 20 655M 20 207M 19 209M 19 825M 19 085M 19 241M 19 406M 19 195M 19 120M 18 772M 18 741M 17 895M 18 244M 17 859M
longTermInvestments 405M 406M 374M 320M 287M 263M 239M 214M 208M 201M 162M 151M 164M 162M
taxAssets 390M 345M 194M 164M 158M 152M 166M 111M 115M 125M 118M 97M 124M 114M
otherNonCurrentAssets 474M 513M 520M 467M 478M 476M 455M 459M 435M 468M 472M 488M 491M 386M
totalNonCurrentAssets 22 748M 22 287M 21 070M 21 548M 20 776M 20 923M 21 085M 20 769M 20 707M 20 411M 20 356M 19 471M 19 926M 19 474M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 28 727M 28 632M 26 899M 27 180M 26 398M 26 574M 26 681M 25 977M 26 036M 25 739M 25 337M 24 223M 24 689M 24 564M
accountPayables 3 550M 3 399M 736M 3 434M 3 313M 3 455M 709M 3 133M 3 007M 3 143M 645M 2 971M 621M 581M
shortTermDebt 2 164M 1 313M 1 145M 1 219M 1 167M 717M 718M 1 309M 1 344M 1 343M 152M 151M 91M 149M
taxPayables 119M 124M 156M 161M 185M 155M 116M 172M 208M 187M 161M 124M 137M 102M
deferredRevenue 0 2 123M 1 779M 1 824M 1 811M 1 914M 1 799M 1 838M 1 844M 1 827M 1 797M 1 842M 1 825M 1 252M
otherCurrentLiabilities 2 675M 613M 1 098M 354M 144M 362M 1 262M 309M 348M 344M 1 132M 165M 1 153M 1 094M
totalCurrentLiabilities 8 508M 7 572M 6 957M 6 992M 6 620M 6 448M 6 491M 6 589M 6 543M 6 657M 5 578M 5 253M 5 241M 4 558M
longTermDebt 13 026M 14 387M 12 838M 12 481M 12 283M 12 819M 12 955M 12 539M 12 675M 12 088M 12 595M 12 502M 12 034M 12 384M
deferredRevenueNonCurrent 0 0 0 0 192M 204M 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 207M 216M 196M 128M 149M 164M 202M 365M 367M 421M 464M 560M 410M 338M
otherNonCurrentLiabilities 698M 671M 668M 612M 632M 595M 698M 679M 703M 641M 671M 561M 649M 633M
totalNonCurrentLiabilities 13 931M 15 274M 13 875M 13 221M 13 064M 13 782M 14 078M 13 583M 13 745M 13 150M 13 994M 13 623M 13 406M 13 726M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 233M 210M 173M 188M 192M 204M 223M 217M 242M 255M 264M 259M 313M 371M
totalLiabilities 22 439M 22 846M 20 832M 20 213M 19 684M 20 230M 20 569M 20 172M 20 288M 19 807M 19 572M 18 876M 18 647M 18 284M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 10 994M 10 952M 10 909M 10 898M 10 853M 3M 3M
retainedEarnings 6 911M 6 580M 6 065M 5 628M 5 343M 4 980M 4 692M 4 223M 3 920M 3 623M 3 334M 3 107M 2 243M 1 277M
accumulatedOtherComprehensiveIncomeLoss -928M -882M -1 038M -826M -949M -911M -867M -903M -760M -731M -727M -898M -406M -205M
othertotalStockholdersEquity 174M 77M 2 162M 2 317M 2 272M -8 509M -8 364M -7 869M 0
totalStockholdersEquity 6 160M 5 778M 6 067M 6 967M 6 714M 6 344M 6 112M 5 805M 5 748M 5 932M 5 765M 5 347M 6 042M 6 001M
totalEquity 6 288M 5 786M 6 067M 6 967M 6 714M 6 344M 6 112M 5 805M 5 748M 5 932M 5 765M 5 347M 6 042M 6 280M
totalLiabilitiesAndStockholdersEquity 28 727M 28 632M 27 180M 26 398M 26 574M 25 977M 26 036M 25 739M 24 223M
minorityInterest 128M 8M 0 0 0 0 0 0 0 0 0 0 0 279M
totalLiabilitiesAndTotalEquity 28 727M 28 632M 26 899M 27 180M 26 398M 26 574M 26 681M 25 977M 26 036M 25 739M 25 337M 24 223M 24 689M 24 564M
totalInvestments 563M 555M 515M 460M 420M 394M 359M 99M 101M 206M 255M 238M 275M 250M
totalDebt 15 190M 15 700M 14 156M 13 700M 13 450M 13 740M 13 896M 13 848M 14 019M 13 431M 13 011M 12 653M 12 438M 12 904M
netDebt 13 376M 13 661M 12 454M 12 128M 11 905M 12 296M 12 520M 12 624M 12 637M 11 937M 11 795M 11 379M 11 072M 11 090M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-15 2022-02-16 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 3 204M 3 381M 2 917M 2 551M 2 410M
otherReceivables 36M 32M 43M 58M 56M
prepaids 154M 141M 151M 156M 159M
totalPayables 892M 825M 806M 758M 683M
otherPayables 156M 116M 161M 137M 102M
accruedExpenses 2 043M 1 887M 1 691M 1 414M 1 380M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 173M 223M 264M 313M 371M
treasuryStock -10 103M -8 741M -7 740M -6 572M -6 166M
additionalPaidInCapital 11 140M 11 025M 10 895M 10 774M 11 092M
otherTotalStockholdersEquity 0 0 -10 895M 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-28 2025-07-22 2024-10-31 2024-07-22 2024-05-02 2023-11-01 2023-08-01 2023-04-28 2022-10-27
acceptedDate 2025-10-28 16:31:55 2025-07-22 07:06:22 2025-02-13 07:39:45 2024-10-31 16:46:54 2024-07-22 16:26:49 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14 2022-02-16 16:22:34 2021-02-12 16:16:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 332M 266M 1 373M 285M 363M 288M 1 358M 303M 297M 289M 1 091M 283M 966M 308M
depreciationAndAmortization 286M 276M 1 114M 278M 269M 264M 1 125M 297M 259M 253M 1 130M 248M 1 264M 1 287M
deferredIncomeTax -46M -45M -129M -34M -14M -66M -269M -47M -43M -27M -115M -24M -138M -176M
stockBasedCompensation 55M 60M 206M 54M 48M 56M 217M 47M 50M 75M 194M 61M 170M 95M
changeInWorkingCapital 452M -104M 158M 151M -82M -16M -280M -22M -156M -175M -84M 278M 680M 459M
accountsReceivables 173M 141M 182M 72M 122M 65M -388M -107M -27M -107M -421M 0 -138M 255M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 115M 0 0 0 267M 0 0 0 427M 0 244M 253M
otherWorkingCapital 279M -245M -139M 79M -82M -16M -159M 85M -129M -68M -90M 366M 574M -49M
otherNonCashItems -171M -10M -6M -13M 590M 580M -2M 5M -5M 2M 44M 17M 0 -14M
netCashProvidedByOperatingActivities 908M 443M 2 716M 721M 588M 522M 2 149M 583M 402M 417M 2 260M 863M 2 942M 1 959M
investmentsInPropertyPlantAndEquipment 293M -151M -602M -150M -143M -145M -649M -146M -160M -164M -674M -165M -640M -616M
acquisitionsNet -456M -195M -710M -447M -54M -142M -876M -428M -432M -25M -1 335M -552M -1 458M -167M
purchasesOfInvestments -1 000 000 -2M -134M 0 -24M -27M -83M -3M 0 -40M -5M -1 000 000 -10M -11M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 3M 0 0 0 0 5M 0
otherInvestingActivites -386M 2M -2M 1 000 000 -27M 1 000 000 -4M 7M 1 000 000
netCashUsedForInvestingActivites -550M -346M -599M -221M -314M -573M -596M -222M -717M
debtRepayment -535M 856M 66M -253M -43M -441M -1 722M -139M -389M
commonStockIssued 0 0 0 -60M 0 0 0 0 0
commonStockRepurchased 1 032M -657M -1 350M -200M 0 0 -992M -144M -490M -129M -1 168M -210M -406M -447M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1 069M -54M -3M -7M -63M 441M 2 307M 355M 348M
netCashUsedProvidedByFinancingActivities -572M 145M -137M -260M -106M -144M 95M 87M -251M
effectOfForexChangesOnCash -11M 57M -68M 42M -6M -34M -4M -24M -13M -4M -75M -49M -52M 31M
netChangeInCash -225M 299M 326M 27M 101M 68M 160M -158M -112M 278M -150M -154M -448M 977M
cashAtEndOfPeriod 1 814M 2 039M 1 702M 1 572M 1 545M 1 444M 1 376M 1 224M 1 382M 1 494M 1 216M 1 274M 1 366M 1 814M
cashAtBeginningOfPeriod 2 039M 1 740M 1 376M 1 545M 1 444M 1 376M 1 216M 1 382M 1 494M 1 216M 1 366M 1 428M 1 814M 837M
operatingCashFlow 908M 443M 2 716M 721M 588M 522M 2 149M 583M 402M 417M 2 260M 863M 2 942M 1 959M
capitalExpenditure 293M -151M -602M -150M -143M -145M -649M -146M -160M -164M -674M -165M -640M -616M
freeCashFlow 1 201M 292M 2 114M 571M 445M 377M 1 500M 437M 242M 253M 1 586M 698M 2 302M 1 343M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-15 2022-02-16 2021-02-12
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 2M 5M 8M 0 -2M
netCashProvidedByInvestingActivities -1 444M -1 603M -2 006M -2 103M -796M
netDebtIssuance 553M 802M 941M 70M 342M
longTermNetDebtIssuance 553M 1 127M 616M 70M 727M
shortTermNetDebtIssuance 0 -325M 325M 0 -385M
netStockIssuance -1 350M -992M -1 168M -406M -447M
netCommonStockIssuance -1 350M -992M -1 168M -406M -447M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -81M -192M -102M -899M -112M
netCashProvidedByFinancingActivities -878M -382M -329M -1 235M -217M
incomeTaxesPaid 295M 340M 255M 222M 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q4
2026-02-05 ET (fiscal 2025 q4)
2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-22 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-06 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-07-22 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-10 ET (fiscal 2022 q4)
2022 q3
2022-10-26 ET (fiscal 2022 q3)
2022 q2
2022-07-21 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-09-03 ET
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
2026-08-27 ET
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
2026-08-20 ET
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
2026-08-17 ET
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
2026-08-04 ET
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
2026-08-04 ET
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
2026-07-28 ET
IQVIA Reports Second-Quarter 2026 Results
2026-07-16 ET
IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
2026-07-08 ET
IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
2026-06-15 ET
Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
2026-06-04 ET
IQVIA Announces Pricing of Senior Notes
2026-06-03 ET
IQVIA Announces Offering of Senior Notes
2026-05-26 20:15 ET
IQVIA CEO to Speak at Jefferies Global Healthcare Conference
2026-05-13 ET
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
2026-05-07 ET
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
2026-05-06 ET
IQVIA CFO to Speak at Bank of America Health Care Conference 2026
2026-05-05 ET
IQVIA Reports First-Quarter 2026 Results
2026-04-15 ET
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026
2026-03-16 ET
IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
2026-03-02 ET
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
2026-03-02 ET
IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference
2026-02-27 ET
IQVIA Releases its 2025 Sustainability Report
2026-02-25 ET
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
2026-02-18 ET
IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day
2026-02-10 ET
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
2026-02-05 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
2026-01-29 ET
IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
2026-01-20 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
2025-12-02 ET
IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform
2025-11-05 ET
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors
2025-10-28 11:00 ET
IQVIA Reports Third-Quarter 2025 Results
2025-10-21 ET
IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025
2025-09-30 ET
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025
2025-09-16 ET
IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships
2025-09-10 ET
IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management
2025-09-02 ET
IQVIA Announces CFO Transition in Early 2026
2025-08-28 ET
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
2025-07-22 ET
IQVIA Reports Second-Quarter 2025 Results
2025-07-01 ET
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
2025-06-16 ET
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement’
2025-06-11 ET
IQVIA Launches New AI Agents for Life Sciences and Healthcare
2025-06-02 ET
IQVIA Announces Pricing of Senior Notes
2025-06-02 ET
IQVIA Announces Offering of Senior Notes
2025-05-27 ET
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
2025-05-16 ET
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
2025-05-07 ET
IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13
2025-05-06 ET
IQVIA Reports First-Quarter 2025 Results
2025-04-28 ET
IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards
2025-04-23 ET
IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm
2025-04-21 ET
IQVIA to Announce First-Quarter 2025 Results on May 6, 2025
2025-04-15 ET
Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report
2025-03-10 ET
IQVIA recognized as a leader in IDC MarketScape’s 2024 assessment for decentralized clinical trial technologies and consulting services
2025-03-04 ET
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
2025-02-24 ET
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
2025-02-21 ET
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
2025-02-20 ET
IQVIA Releases 2024 Sustainability Report
2025-02-06 ET
IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance
2025-02-04 ET
IQVIA named to the Fortune® World’s Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year
2025-01-21 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025
2025-01-13 ET
IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions
2024-12-23 ET
Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
2024-11-06 ET
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
2024-10-31 11:00 ET
IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day
2024-10-15 20:15 ET
IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024
2024-10-02 13:00 ET
IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™
2024-09-19 13:00 ET
IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award
2024-09-04 13:00 ET
Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative
2024-08-21 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024
2024-07-22 11:00 ET
IQVIA Reports Second-Quarter 2024 Results
2024-07-11 12:30 ET
IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group
2024-07-08 20:15 ET
IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024
2024-06-25 12:00 ET
IQVIA’s SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”
2024-06-12 12:00 ET
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
2024-06-10 12:00 ET
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
2024-05-14 12:00 ET
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
2024-05-09 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024
2024-05-02 11:00 ET
IQVIA Reports First-Quarter 2024 Results
2024-04-23 13:00 ET
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
2024-04-15 20:15 ET
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
2024-04-08 20:01 ET
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
2024-02-26 13:00 ET
IQVIA Publishes its 2023 Environmental, Social and Governance Report
2024-02-23 14:00 ET
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
2024-02-21 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024
2024-02-14 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
2024-02-06 14:00 ET
IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year
2024-01-24 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
2024-01-17 11:00 ET
Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report
2024-01-17 ET
Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report
2023-11-29 13:30 ET
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
2023-11-21 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023
2023-11-17 14:23 ET
IQVIA Announces Upsizing of its Allocation of New Term B Loans
2023-11-15 14:11 ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes
2023-11-14 14:07 ET
IQVIA Announces Offering of Senior Secured Notes
2023-11-06 13:00 ET
IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
2023-11-01 11:00 ET
IQVIA Reports Third-Quarter 2023 Results
2023-10-23 12:00 ET
IQVIA to Provide Sanofi Its Orchestrated Customer Engagement (OCE) Platform in Africa & Middle East
2023-10-11 11:30 ET
IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission
2023-10-09 20:15 ET
IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023
2023-10-05 12:00 ET
Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science
2023-10-05 ET
Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science
2023-10-03 12:00 ET
IQVIA Builds on its Strategic Collaboration with argenx to Provide Safety Systems and Services
2023-09-26 00:01 ET
IQVIA Appoints Richard Staub III President of Research & Development Solutions
2023-09-12 12:30 ET
IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report
2023-09-05 12:30 ET
IQVIA CFO Ron Bruehlman to Speak at Baird Global Healthcare Conference on September 13, 2023
2023-09-01 12:30 ET
IQVIA CEO Ari Bousbib to Speak at Morgan Stanley Annual Global Healthcare Conference on September 12, 2023
2023-08-01 11:00 ET
IQVIA Reports Second-Quarter 2023 Results
2023-07-06 20:15 ET
IQVIA to Announce Second-Quarter 2023 Results on August 1, 2023
2023-07-05 15:00 ET
IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award
2023-06-29 12:30 ET
IQVIA selected ‘Leader’ in Everest Group Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023
2023-06-27 13:30 ET
IQVIA Wins Prestigious “Best AI-based Solution for Healthcare” Award in 2023 Artificial Intelligence Breakthrough Awards
2023-06-26 12:30 ET
IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management
2023-05-25 06:00 ET
IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
2023-05-24 12:00 ET
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
2023-05-18 20:38 ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes
2023-05-18 12:25 ET
IQVIA Announces Offering of Senior Secured Notes and Senior Notes
2023-05-11 15:00 ET
IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award
2023-05-02 12:00 ET
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
2023-04-27 11:00 ET
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
2023-04-20 15:00 ET
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
2023-04-06 20:15 ET
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
2023-03-14 12:00 ET
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
2023-03-01 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
2023-02-23 16:00 ET
IQVIA Publishes its 2022 Environmental, Social and Governance Report
2023-02-10 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance
2023-02-09 17:00 ET
IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
2023-01-31 13:30 ET
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
2023-01-25 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
2023-01-18 13:00 ET
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
2023-01-03 16:05 ET
Lasso announces a significant step forward in healthcare marketing measurement
2022-12-28 13:30 ET
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
2022-11-10 16:00 ET
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
2022-10-26 11:00 ET
IQVIA Reports Third-Quarter 2022 Results
2022-10-24 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
2022-10-06 12:15 ET
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
2022-10-03 20:15 ET
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
2022-09-28 14:00 ET
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
2022-09-07 12:15 ET
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
2022-09-02 12:15 ET
IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022
2022-09-01 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022
2022-08-15 11:30 ET
IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award
2022-07-21 11:00 ET
IQVIA Reports Second-Quarter 2022 Results
2022-07-07 20:15 ET
IQVIA to Announce Second-Quarter 2022 Results on July 21, 2022
2022-07-06 11:30 ET
IQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Services
2022-06-07 12:00 ET
IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions
2022-06-01 12:00 ET
Global Oncology R&D Surges While Cancer Care Disruptions Ease, Says IQVIA Institute for Human Data Science
2022-05-25 20:43 ET
IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
2022-04-27 11:00 ET
IQVIA Reports First-Quarter 2022 Results
2022-04-21 12:00 ET
Spending on U.S. Medicines Rose 12% in 2021 Due to COVID-19 Vaccines and Therapies, Says IQVIA Institute for Human Data Science
2022-04-12 20:15 ET
IQVIA to Announce First-Quarter 2022 Results on April 27, 2022
2022-03-30 22:00 ET
IQVIA Selected to Support EMA’s DARWIN EU® Coordination Centre Initiative
2022-03-15 22:05 ET
IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement
2022-03-14 13:00 ET
IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)
2022-03-03 21:15 ET
IQVIA CFO to Speak at Barclays Global Healthcare Conference on March 16, 2022
2022-03-01 13:00 ET
IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE
2022-02-24 13:00 ET
IQVIA Named Top CRO in 2021 WCG CenterWatch Independent Survey
2022-02-22 13:00 ET
IQVIA Releases 2021 Environmental, Social, and Governance (ESG) Report
2022-02-15 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2021 Results; Raises Full-Year 2022 Profit Guidance
2022-02-10 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s 2022 Virtual Healthcare Conference on February 24, 2022
2022-02-10 13:00 ET
Pharma R&D Pipeline and New Product Launches Reach Record Levels in 2021 According to New IQVIA Institute for Human Data Science Report
2022-02-02 13:40 ET
IQVIA Named to FORTUNE’s 2022 List of “World’s Most Admired Companies,” Ranked #1 in Health Care: Pharmacy and Other Services
2022-02-01 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2021 Results on February 15, 2022
2022-01-26 22:01 ET
Sheila A. Stamps Joins IQVIA Board of Directors
2022-01-24 22:00 ET
Leslie Wims Morris Joins IQVIA Board of Directors
2021-12-09 13:00 ET
Global Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19 Vaccines, According to Study by the IQVIA Institute for Human Data Science
2021-12-06 12:00 ET
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
2021-12-02 13:00 ET
IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit
2021-12-01 13:00 ET
IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing
2021-11-18 13:00 ET
IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform
2021-10-21 11:00 ET
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
2021-10-12 12:00 ET
IQVIA to Announce Third-Quarter 2021 Results on October 21, 2021
2021-10-07 15:00 ET
IQVIA to Host Financial Analyst and Investor Conference on November 16, 2021
2021-10-06 12:00 ET
IQVIA Announces Opening of New Q² Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities
2021-09-30 12:00 ET
Polpharma Selects IQVIA's Orchestrated Customer Engagement Platform to Improve Salesforce Productivity
2021-09-13 20:15 ET
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
2021-09-08 12:00 ET
IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real-World Data
2021-09-02 20:15 ET
IQVIA CFO, Ron Bruehlman, to Speak at the Baird 2021 Global Healthcare Conference on September 14, 2021
2021-09-01 12:00 ET
IQVIA Launches New A.I.-Powered MI Contact Center For Life Sciences
2021-07-27 11:00 ET
IQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance
2021-07-22 12:00 ET
Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute
2021-07-13 20:15 ET
IQVIA to Announce Second-Quarter 2021 Results on July 27, 2021
2021-06-24 20:15 ET
IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials
2021-06-14 12:00 ET
Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
2021-06-08 12:00 ET
Q² Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
2021-06-03 20:30 ET
Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015, Says New Report from the IQVIA Institute for Human Data Science
2021-05-20 20:15 ET
IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021
2021-05-19 12:00 ET
Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science
2021-05-12 12:00 ET
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
2021-05-11 13:03 ET
Despite Disinformation Attempt, Antitrust Case Against IQVIA Moves Forward and Report of FTC Investigation of IQVIA Comes to Light
2021-05-10 12:00 ET
U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
2021-05-03 12:00 ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
2021-04-29 12:00 ET
Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study
2021-04-28 12:00 ET
IQVIA Announces Connected Intelligence™
2021-04-22 11:00 ET
IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance
2021-04-06 17:00 ET
IQVIA to Announce First-Quarter 2021 Results on April 22, 2021
2021-04-06 11:30 ET
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
2021-04-01 11:03 ET
Quest Diagnostics Sells Ownership Interest in Q² Solutions to IQVIA
2021-04-01 11:00 ET
IQVIA Acquires Remaining Interest in Q² Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance
2021-03-09 13:00 ET
IQVIA Virtual Trial Solutions Used in More than 60 Trials
2021-03-08 13:00 ET
IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
2021-03-02 21:15 ET
IQVIA to Participate in the Barclays Global Healthcare Conference on March 09, 2021
2021-02-17 21:27 ET
IQVIA Announces Pricing of Offering of Senior Notes
2021-02-16 08:26 ET
IQVIA Announces Offering of Senior Notes
2021-02-11 13:00 ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries
2021-02-10 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance
2021-02-04 13:00 ET
IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report
2021-02-01 13:00 ET
IQVIA Named to FORTUNE’s 2021 List of “World’s Most Admired Companies”
2021-01-26 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021
2021-01-05 13:00 ET
Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation
2020-12-21 12:30 ET
Q² Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
2020-12-17 13:00 ET
Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA™ Institute for Human Data Science
2020-12-16 13:00 ET
IQVIA and Servier Collaborate to Reinvent Clinical Development
2020-12-07 13:00 ET
IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence
2020-11-02 13:00 ET
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities
2020-10-20 11:00 ET
IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook
2020-10-12 12:00 ET
IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project
2020-10-07 20:15 ET
IQVIA to Announce Third-Quarter Results on October 20, 2020
2020-10-06 12:00 ET
IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
2020-09-14 12:10 ET
IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award
2020-08-31 12:58 ET
IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards®
2020-08-05 12:00 ET
IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards
2020-08-04 12:00 ET
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
2020-07-29 12:00 ET
IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness
2020-07-23 12:00 ET
IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers
2020-07-22 11:00 ET
IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance
2020-07-21 22:00 ET
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
2020-07-21 22:00 ET
IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer
2020-07-20 12:01 ET
IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data
2020-07-14 12:00 ET
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
2020-07-08 20:15 ET
IQVIA to Announce Second-Quarter Results on July 22, 2020
2020-07-02 12:00 ET
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
2020-06-10 21:58 ET
IQVIA Announces Pricing of Offering of Senior Notes
2020-04-28 11:00 ET
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
2020-02-13 21:41 ET
IQVIA Announces Repurchase of Common Stock
2020-02-12 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance
2020-01-29 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020
2020-01-21 13:00 ET
IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”

SEC forms

Show financial reports only

SEC form 10
2026-07-28 20:38 ET
IQVIA published news for 2026 q2
SEC form 8
2026-07-28 11:03 ET
IQVIA published news for 2026 q2
SEC form 8
2026-07-28 11:03 ET
IQVIA published news for 2026 q2
SEC form 8
2026-06-04 21:08 ET
IQVIA published news for 2026 q1
SEC form 8
2026-06-04 21:08 ET
IQVIA published news for 2026 q1
SEC form 8
2026-06-03 20:45 ET
IQVIA published news for 2026 q1
SEC form 8
2026-06-03 20:45 ET
IQVIA published news for 2026 q1
SEC form 8
2026-05-07 21:24 ET
IQVIA published news for 2026 q1
SEC form 8
2026-05-07 21:24 ET
IQVIA published news for 2026 q1
SEC form 10
2026-05-05 20:42 ET
IQVIA published news for 2026 q1
SEC form 8
2026-05-05 11:03 ET
IQVIA published news for 2026 q1
SEC form 8
2026-05-05 11:03 ET
IQVIA published news for 2026 q1
SEC form 10
2026-02-17 12:46 ET
IQVIA published news for 2025 q4
SEC form 8
2026-02-05 07:04 ET
IQVIA published news for 2025 q4
SEC form 8
2026-02-05 07:04 ET
IQVIA reported for 2025 q4
SEC form 10
2025-10-28 20:31 ET
IQVIA reported for 2025 q3
SEC form 8
2025-10-28 11:05 ET
IQVIA published news for 2025 q3
SEC form 8
2025-10-28 11:05 ET
IQVIA reported for 2025 q3
SEC form 10
2025-07-22 20:50 ET
IQVIA published news for 2025 q2
SEC form 10
2025-07-22 00:00 ET
IQVIA reported for 2025 q2
SEC form 8
2025-07-22 00:00 ET
IQVIA published news for 2025 q2
SEC form 8
2025-07-22 00:00 ET
IQVIA reported for 2025 q2
SEC form 8
2025-06-02 21:22 ET
IQVIA published news for 2025 q1
SEC form 8
2025-06-02 21:22 ET
IQVIA published news for 2025 q1
SEC form 8
2025-06-02 21:22 ET
IQVIA published news for 2025 q1
SEC form 10
2025-05-06 20:40 ET
IQVIA reported for 2025 q1
SEC form 8
2025-05-06 11:04 ET
IQVIA published news for 2025 q1
SEC form 8
2025-05-06 11:04 ET
IQVIA reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
IQVIA reported for 2025 q1
SEC form 10
2025-02-13 00:00 ET
IQVIA published news for 2024 q4
SEC form 8
2025-02-06 07:04 ET
IQVIA published news for 2024 q4
SEC form 8
2025-02-06 07:04 ET
IQVIA reported for 2024 q4
SEC form 10
2024-10-31 16:46 ET
IQVIA reported for 2024 q3
SEC form 8
2024-10-31 07:05 ET
IQVIA published news for 2024 q3
SEC form 8
2024-10-31 07:05 ET
IQVIA reported for 2024 q3
SEC form 10
2024-10-31 00:00 ET
IQVIA reported for 2024 q3
SEC form 10
2024-07-22 16:26 ET
IQVIA published news for 2024 q2
SEC form 8
2024-07-22 07:05 ET
IQVIA published news for 2024 q2
SEC form 8
2024-07-22 07:05 ET
IQVIA reported for 2024 q2
SEC form 10
2024-07-22 00:00 ET
IQVIA published news for 2024 q2
SEC form 10
2024-05-02 16:32 ET
IQVIA published news for 2024 q1
SEC form 8
2024-05-02 08:41 ET
IQVIA published news for 2024 q1
SEC form 8
2024-05-02 08:41 ET
IQVIA reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
IQVIA published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
IQVIA reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
IQVIA published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
IQVIA published news for 2023 q4
SEC form 10
2023-11-01 16:29 ET
IQVIA published news for 2023 q3
SEC form 8
2023-11-01 07:05 ET
IQVIA reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
IQVIA published news for 2023 q3
SEC form 10
2023-08-01 16:22 ET
IQVIA published news for 2023 q2
SEC form 6
2023-08-01 07:05 ET
IQVIA reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
IQVIA published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
IQVIA published news for 2023 q2
SEC form 10
2023-04-28 00:00 ET
IQVIA published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
IQVIA published news for 2023 q1
SEC form 6
2023-04-17 19:45 ET
IQVIA published news for 2023 q1
SEC form 10
2023-02-15 16:24 ET
IQVIA reported for 2022 q4
SEC form 10
2023-02-15 00:00 ET
IQVIA reported for 2022 q4
SEC form 6
2023-02-13 16:31 ET
IQVIA published news for 2022 q4
SEC form 6
2023-02-10 07:02 ET
IQVIA published news for 2022 q4
SEC form 8
2023-02-10 00:00 ET
IQVIA reported for 2022 q4
SEC form 10
2022-10-27 16:24 ET
IQVIA reported for 2022 q3
SEC form 10
2022-10-27 00:00 ET
IQVIA reported for 2022 q3
SEC form 6
2022-10-26 07:05 ET
IQVIA published news for 2022 q3
SEC form 8
2022-10-26 00:00 ET
IQVIA reported for 2022 q3
SEC form 6
2022-10-03 07:00 ET
IQVIA published news for 2022 q3
SEC form 6
2022-08-05 17:18 ET
IQVIA published news for 2022 q2
SEC form 6
2022-07-29 16:15 ET
IQVIA published news for 2022 q2
SEC form 10
2022-07-22 16:22 ET
IQVIA reported for 2022 q2
SEC form 10
2022-07-22 00:00 ET
IQVIA reported for 2022 q2
SEC form 6
2022-07-21 07:05 ET
IQVIA published news for 2022 q2
SEC form 8
2022-07-21 00:00 ET
IQVIA reported for 2022 q2
SEC form 6
2022-06-16 17:26 ET
IQVIA published news for 2022 q1
SEC form 10
2022-04-28 16:18 ET
IQVIA reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
IQVIA reported for 2022 q1
SEC form 6
2022-04-27 07:05 ET
IQVIA published news for 2022 q1
SEC form 8
2022-04-27 00:00 ET
IQVIA reported for 2022 q1
SEC form 6
2022-04-14 16:48 ET
IQVIA published news for 2022 q1
SEC form 6
2022-03-17 17:05 ET
IQVIA published news for 2021 q4
SEC form 6
2022-03-14 17:03 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-28 16:48 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-18 16:44 ET
IQVIA published news for 2021 q4
SEC form 10
2022-02-16 16:22 ET
IQVIA published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-15 07:05 ET
IQVIA published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-02 17:08 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-02 17:03 ET
IQVIA published news for 2021 q4
SEC form 6
2022-01-26 17:46 ET
IQVIA published news for 2021 q4
SEC form 10
2021-10-22 07:55 ET
IQVIA published news for 2021 q3
SEC form 10
2021-10-22 00:00 ET
IQVIA published news for 2021 q3
SEC form 6
2021-10-21 07:05 ET
IQVIA published news for 2021 q3
SEC form 8
2021-10-21 00:00 ET
IQVIA published news for 2021 q3
SEC form 6
2021-08-25 16:54 ET
IQVIA published news for 2021 q2
SEC form 10
2021-07-28 16:14 ET
IQVIA published news for 2021 q2
SEC form 10
2021-07-28 00:00 ET
IQVIA published news for 2021 q2
SEC form 6
2021-07-27 07:05 ET
IQVIA published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
IQVIA reported for 2021 q2
SEC form 10
2021-04-23 16:12 ET
IQVIA published news for 2021 q1
SEC form 10
2021-04-23 00:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-22 07:05 ET
IQVIA published news for 2021 q1
SEC form 8
2021-04-22 00:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-16 17:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-01 07:05 ET
IQVIA published news for 2021 q1
SEC form 6
2021-03-03 16:39 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-26 17:19 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-17 16:44 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-16 17:06 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-16 06:20 ET
IQVIA published news for 2020 q4
SEC form 10
2021-02-12 16:16 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-10 07:05 ET
IQVIA published news for 2020 q4
SEC form 10
2020-10-22 16:05 ET
IQVIA published news for 2020 q3
SEC form 6
2020-10-20 07:05 ET
IQVIA published news for 2020 q3